Relcovaptan

Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results for the treatment of Raynaud's disease and dysmenorrhoea, and as a tocolytic,[2] although it is not yet approved for clinical use.

Relcovaptan
Clinical data
Other names(2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H27Cl2N3O7S
Molar mass620.50 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

References

  1. Lemmens-Gruber R, Kamyar M (August 2006). "Vasopressin antagonists". Cellular and Molecular Life Sciences. 63 (15): 1766–79. doi:10.1007/s00018-006-6054-2. PMID 16794787.
  2. Decaux G, Soupart A, Vassart G (May 2008). "Non-peptide arginine-vasopressin antagonists: the vaptans". Lancet. 371 (9624): 1624–32. doi:10.1016/S0140-6736(08)60695-9. PMID 18468546.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.